FIGURE 6.

Anti‐programmed cell death‐ligand 1 (PD‐L1) antibody treatment delays tumor growth and improves survival of MOC1‐A tumor‐bearing mice. (A) Seven‐day post MOC1‐A tumor implantation. The MOC1‐A tumor‐bearing mice were treated with intraperitoneal injection of isotype control IgG antibody or anti‐PD‐L1 antibody for a total of 10 injections. Tumor volumes were recorded twice per week. (B) Kaplan–Meier survival analysis for IgG antibody or anti‐PD‐L1 antibody treated MOC1‐A tumor‐bearing mice (n = 10/group). (C–E) Flow cytometric characterization of the presence of total CD3+ T cells within tumors from MOC1‐A tumor‐bearing mice with IgG antibody or anti‐PD‐L1 antibody treatment (C). Cells shown in (C) were further gated CD8+ (D) or CD4+ (E). Absolute numbers of indicated cells per 1× 10⁴ cells collected are displayed (n = 10/group). (F) The expression levels of interferon gamma (IFN‐γ), TNF‐α, and interleukin‐2 (IL‐2) within tumors from MOC1‐A tumor‐bearing mice with IgG antibody or anti‐PD‐L1 antibody treatment were assessed by RT‐qPCR assay. *P < 0.05